ArticleNeuro-oncology2017
CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone.
Open access · bronzeAbstract read
In one paragraph
Article in Neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 119 citations in OpenAlex.
- The intersection of chemokine signaling with the hallmarks of cancer in glioblastoma.Journal of neuro-oncology · 2026Review
- Prolactin-Releasing Hormone Receptor (PRLHR) enhances radiosensitivity and exacerbates DNA damage in glioblastoma post-irradiation by inhibiting Y-box-binding protein-1 (YBX1) nuclear translocation: a novel perspective on precision radiotherapy.Molecular biomedicine · 2026Article
- Pharmacological modulation of CXCL12/CXCR4/ACKR3 for brain disorders - an overview.Cell communication and signaling : CCS · 2026Review
- Review
- Assessment of subventricular zone irradiation in glioblastoma patients.Frontiers in oncology · 2026Article
- Immune-tumor cell ligand-receptor axes driving metabolic reprogramming and therapeutic resistance in cancer.Frontiers in immunology · 2026Review
- An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with glioblastoma cells' stemness features and migration.Molecular therapy. Oncology · 2025Article
- CXCR4 confers stemness and radioresistance in chordoma cells.Cancer biology & therapy · 2025Article
- Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma.Tomography (Ann Arbor, Mich.) · 2025Article
- GliaTrap is a biodegradable, non-swelling and non-inflammatory hydrogel with tuned release of CXCL12 to attract migrating glioblastoma cells.Scientific reports · 2025Article
- The subventricular zone structure, function and implications for neurological disease.Genes & diseases · 2025Review
- Glioblastoma drives protease-independent extracellular matrix invasion of microglia.Materials today. Bio · 2025Article
- Non-Immune-Mediated, p27-Associated, Growth Inhibition of Glioblastoma by Class-II-Transactivator (CIITA).Cells · 2024Article
- Heterogeneous expression of the atypical chemokine receptor ACKR3 in glioblastoma patient-derived tissue samples and cell cultures.Scientific reports · 2024Article
- Risk Factors of Distant Recurrence and Dissemination ofCancers · 2024Review
- Article
- Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma.EJNMMI radiopharmacy and chemistry · 2024Article
- CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity.Cell death & disease · 2024Article
- Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.Journal of hematology & oncology · 2024Review
- CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.Journal of cancer research and clinical oncology · 2023Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Nicolas GoffartLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Arnaud LombardLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
François LallemandLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Jérôme KroonenLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Jessica NassenLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Emmanuel Di ValentinLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Sharon BerendsenLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.) bernard.rogister@ulg.ac.be.
Matthias DedobbeleerLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Estelle WillemsLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Pierre RobeLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Vincent BoursLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Didier MartinLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Philippe MartiniveLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Pierre MaquetLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
Bernard RogisterLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.L., J.N., M.D., E.W., B.R.); Department of Neurosurgery, CHU and University of Liège, Liège, Belgium (A.L., D.M.); Department of Radiotherapy and Oncology, CHU and University of Liège, Liège, Belgium (F.L., P.M.); Laboratory of Tumor and Development Biology, GIGA-Cancer Research Center, University of Liège, Liège, Belgium (F.L.); Cyclotron Research Centre, University of Liège, Liège, Belgium (F.L.); Human Genetics, CHU and University of Liège, Liège, Belgium (N.G., J.K., V.B.); Department of Neurosurgery, Brain Center Rudolf Magnus Institute of Neurosciences and the T&P Bohnenn Laboratory for Neuro-Oncology University Medical Center, Utrecht, The Netherlands (N.G., J.K., S.B., P.R.); GIGA-Viral Vector Plateform, University of Liège, Liège, Belgium (E.D.V.); Department of Neurology, CHU and University of Liège, Liège, Belgium (P.M., B.R.).
University of Liège · BE
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with glioblastoma (GBM) have an overall median survival of 15 months despite multimodal therapy. These catastrophic survival rates are to be correlated to systematic relapses that might arise from remaining glioblastoma stem cells (GSCs) left behind after surgery. In this line, it has recently been demonstrated that GSCs are able to escape the tumor mass and preferentially colonize the adult subventricular zone (SVZ). At a distance from the initial tumor site, these GSCs might therefore represent a high-quality model of clinical resilience to therapy and cancer relapses as they specifically retain tumor-initiating abilities.
methodWhile relying on recent findings that have validated the existence of GSCs in the human SVZ, we questioned the role of the SVZ niche as a potential GSC reservoir involved in therapeutic failure.
resultsOur results demonstrate that (i) GSCs located in the SVZ are specifically resistant to radiation in vivo, (ii) these cells display enhanced mesenchymal roots that are known to be associated with cancer radioresistance, (iii) these mesenchymal traits are specifically upregulated by CXCL12 (stromal cell-derived factor-1) both in vitro and in the SVZ environment, (iv) the amount of SVZ-released CXCL12 mediates GBM resistance to radiation in vitro, and (v) interferes with the CXCL12/CXCR4 signalling system, allowing weakening of the tumor mesenchymal roots and radiosensitizing SVZ-nested GBM cells.
conclusionTogether, these data provide evidence on how the adult SVZ environment, through the release of CXCL12, supports GBM therapeutic failure and potential tumor relapse.
Indexed as
Radiation ToleranceAnimalsBrain NeoplasmsChemokine CXCL12Cranial IrradiationGamma RaysGlioblastomaHumansLateral VentriclesMiceMice, NudeNeoplastic Stem CellsSignal TransductionTumor Cells, CulturedChemokine CXCL12CXCL12 protein, humanCXCL12glioblastomamesenchymal activationradioresistancesubventricular zone
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.